Directors

Craig H. Misrach, M.B.A., C.P.A. – Chairman

Craig H. Misrach is the President and Chief Executive Officer of Freedom Meditech and has over 10 years of finance experience with start-up and midsize organizations.  Prior to Freedom Meditech, Mr. Misrach was the President and Chief Operating Officer of EyeChem, a developmental stage diabetes medical device company focused on the commercialization of an eye-related blood glucose measuring and monitoring system. At EyeChem, Mr. Misrach crafted and executed the financing, operating, and marketing strategies of the organization while simultaneously overseeing the contract manufacturing and product development activities of the company.  Mr. Misrach was successful in obtaining initial start-up capital and infrastructure support for the organization.

Prior to EyeChem, Mr. Misrach was Controller and Assistant Vice President of Silvergate Capital Corporation, a $500M asset-based diversified finance organization.  At Silvergate, Mr. Misrach was the primary liaison for executive management regarding the revenue and expense activities of the organization and gained extensive operational and management experience during a two year period of fast-paced corporate growth from 28 to 79 employees.  Silvergate was a client of Mr. Misrach at Deloitte and Touché, where he was the Lead Senior Accountant for a $60M IPO and audited various biotechnology, medical device, and healthcare companies.

Mr. Misrach is a Certified Public Accountant (C.P.A.) in the State of California and has a B.S. in Accounting and Finance from Indiana University.  Mr. Misrach also has an M.B.A. in General Management and Entrepreneurship & Venture Capital from the Darden Graduate School of Business at the University of Virginia.

Keith D. Ignotz, M.B.A. – Director

Mr. Ignotz is currently the CEO of DiaKine Therapeutics, a start-up biopharmaceutical company developing new, proprietary drugs for unmet diabetes medical needs.  Mr. Ignotz is a senior corporate executive with over 25 years of experience in the global healthcare marketplace, with 14 such years in the diabetes space.  Mr. Ignotz joined DiaKine from SpectRx, Inc., a diabetes management company which he co-founded in 1993 and where he served as President and Chief Operating Officer. While in that position, he raised over $6.5 million in venture capital funding, negotiated a $26.5 million strategic partnering collaboration and brought the Company through an IPO. Previously, he was President of Humphrey Instruments SmithKline Beckman (Japan) and Humphrey Instruments (Germany), and Senior Vice President of Allergan Humphrey. Mr. Ignotz has a B.A. from San Jose State University and an M.B.A. from Pepperdine University.